Piper Sandler Starts Janux Therapeutics (JANX) at Overweight

Piper Sandler analyst Kelsey Goodwin initiates coverage on Janux Therapeutics (NASDAQ: JANX) with a Overweight rating and a price target of $42.00.

The analyst comments "Following highly positive reception to JANX007 clinical data in mCRPC in December 2024, investor sentiment has waned over the course of 2025 following the emergence of competitor clinical data, and the announcement of completion of the JANX007 dose escalation. We continue to think JANX007 is a differentiated, potentially best-in-class program in mCRPC and see the stock pull-back as offering an attractive entry point as we head into the clinical update later this year."

For an analyst ratings summary and ratings history on Janux Therapeutics click here. For more ratings news on Janux Therapeutics click here.

Shares of Janux Therapeutics closed at $25.11 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Smith-Midland receives Nasdaq notice for late quarterly filing
• Fuerte changes name to Talamore Mining, shares to trade as TALA